Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupRPGLF 14 Cash-to-Debt is 0.04 as of Dec. 2025, which is 93% below its 10-year median of 0.58. GuruFocus rates RPGLF with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 982 Drug Manufacturers companies, Regent Pacific Group ranks worse than 92.77% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Regent Pacific Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.04.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Regent Pacific Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Regent Pacific Group's Cash-to-Debt or its related term are showing as below:
RPGLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.58 Max: No Debt
Current: 0.04
During the past 13 years, Regent Pacific Group's highest Cash to Debt Ratio was No Debt. The lowest was 0.04. And the median was 0.58.
RPGLF's Cash-to-Debt is ranked worse than 92.77% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs RPGLF: 0.04
Regent Pacific Group (OTCPK:RPGLF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Regent Pacific Group Cash-to-Debt Related Terms
Regent Pacific Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Regent Pacific Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regent Pacific Group (RPGLF) has a Cash-to-Debt of 0.04 as of Dec. 2025. This is 93% below median its historical median of 0.58. Over the past decade, Regent Pacific Group's Cash-to-Debt has ranged from 0.04 to 10,000.00. According to the industry distribution chart, Regent Pacific Group ranks #911 out of 982 companies in the Drug Manufacturers industry, placing it in the top 92.8%.
Is Regent Pacific Group's Cash-to-Debt too high?
Regent Pacific Group's current Cash-to-Debt of 0.04 is 93% below median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.97. Regent Pacific Group's value of 0.04 is 95.9% below this industry median. Based on the distribution chart, Regent Pacific Group ranks #911 out of 982 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regent Pacific Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #911 out of 982 companies for Cash-to-Debt. This places Regent Pacific Group in the lower half of its industry. The industry median Cash-to-Debt is 0.97. Regent Pacific Group's value of 0.04 is 95.9% below this benchmark. Historically, Regent Pacific Group's own Cash-to-Debt has ranged from 0.04 to 10,000.00 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 0.97, Regent Pacific Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regent Pacific Group's current Cash-to-Debt of 0.04 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current Cash-to-Debt is 0.04, which is 93% below median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current Cash-to-Debt of 0.04. The current Cash-to-Debt is 0.04, which is 93% below median its 10-year median of 0.58 and 95.9% below the Drug Manufacturers industry median of 0.97. Regent Pacific Group's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current Cash-to-Debt is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
14GF Score
Get the complete analysis for RPGLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
